The current approach for carcinogenicity testing usually incorporates a genetic toxicity screen, 14-and 90day subchronic toxicity studies in rats and mice, toxicokinetic and disposition studies, and 2-yr chronic bioassays in rats and mice. The 2-yr bioassays are both time and resource intensive, and questions have been raised regarding the relevance of some of the carcinogenic responses in rodents for human risk assessment. At the 1996 meeting of the International Conference on Harmonization (ICH) Expert Working Group on Safety, the international pharmaceutical and regulatory communities acknowledged the limited utility of certain aspects of conventional rodent studies and proposed a new scheme for carcinogenicity testing for pharmaceuticals (Fed. Reg. 61: 43298-43300). The proposed strategy incorporates a conventional bioassay in a single rodent species and the option to conduct a short-or medium-term in vivo assay with a tumor end point in place of the second species bioassay. The available alternative models include initiation-promotion assays, newborn rodent assays, and several transgenic mouse assays that have recently been developed. The willingness of the regulatory authorities to accept data from these new experimental approaches as part of the safety assessment process for pharmaceuticals has stimulated international interest in gaining experience and a greater understanding of the strengths and limitations of the specific models. These new methods have not been fully characterized, and the scientific community is considering their most appropriate application(s).
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The Alternatives to Carcinogenicity Testing Technical Committee was formed under the auspices of the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute to assist in the further evaluation of these new experimental approaches for carcinogenicity testing. Through the efforts of this committee, which is composed of interested scientists from industry, government, and academia, an international collaborative research program was established. The goals of this research program, currently being conducted in more than 45 laboratories in the United States, Europe, and Japan, are: to expand the data base on several of these new test methods; to enhance the understanding of the specific responses of each model to compounds representing a range of chemical and pharmaceuticalltherapeutic classes, including various modes of toxic and carcinogenic action; to evaluate potential criteria that should be considered in the selection of one model over another for a particular * Address correspondence to: Denise Robinson, International Life Sciences Institute, 1 126 Sixteenth Street NW, Washington. D.C. 20036. application; and to contribute to a sound scientific basis for understanding and appropriate use of data from these alternative models for the assessment of the carcinogenic potential of chemicals to humans.
The transgenic models that are being investigated through this collaborative research program include the Tg-rusH2 transgenic mouse, the Tg. AC transgenic mouse (both dermal and oral routes of exposure), the p53+'knockout mouse, the xpa repair-deficient transgenic mouse, the neonatal mouse, and the Syrian hamster embryo cell transformation assay.
The intent of the research program has been to complement and augment the studies conducted by the National Institute for Environmental Health Sciences (p53+'and Tg.AC models), the Central Insitute for Experimental Animals in Japan (Tg-msH2 model), the US Food and Drug Administration's National Center for Toxicological Research (neonatal mouse model), and the National Institute of Public Health and the Environment (RIVM, Netherlands) (xpa-l-model). The compounds initially tested by these groups were primarily genotoxic industrial and environmental agents; thus, the ILSI program has focused primarily on pharmaceutical compounds (Table I) .
Pharmaceuticals offer a particularly rich source of data relevant to human risk assessment, because often extensive data are available on the extent of human exposure and on the similarities and differences between animals and humans in pharmacodynamics and pharmacokinetics. The specific chemicals selected will provide data regarding a number of potential modes of carcinogenic action as well as different chemical and therapeutic classes. Selection criteria for the compounds to be tested were the availability of long-term carcinogenicity data (in both rats and mice), genotoxicity and other data on mode/mechanism of carcinogenic action, and, where possible, human (clinical trial or epidemiology) data. Several nonpharmaceutical compounds that met these criteria were also included, particularly where significant mechanistic understanding existed. Based on the available data, the compounds selected were classified as either human carcinogens, rodent carcinogens/putative human noncarcinogens (either on the basis of mechanistic data or human evidence), and noncarcinogens (Table I) . Modes of carcinogenic action included mutagenicity, cytotoxicity and regenerative cell proliferation, liver enzyme induction, peroxisome proliferation, and other receptor-mediated or nongenotoxic mechanisms. Standardized protocols were developed for each of the assays and prepared in a harmonized format to facilitate comparisons of methodologies among the different assays. Standard protocols will establish a common experimental approach that will facilitate the comparability and reproducibility of data obtained in multiple laboratories. The intent is to be able to compare the results on each chemical across the various assays as well as to evaluate the range of compounds tested within a given assay. Although there Compounds are to be tested for 26 wk (1 yr for the neonatal assay). Route of administration is to be similar to the anticipated human route of exposure (except with the Tg.AC dermal assay). Three dose groups plus a vehicle control group will be tested.
A positive control compound is recommended to ensure that each laboratory can elicit a positive response from the specific model (Table 11 ). Doses will be selected on the basis of a 4-wk dose range finding study, using measures of dose related to the mode of carcinogenicity/toxicity, where possible. A nontransgenic vehicle control and a high-dose group are recommended to assess each model's potential for enhanced response or reduced time to tumor. Toxicokinetics will be determined to assess systemic exposure of test compound as well as to gain understanding of metabolic and kinetic characteristics of models. A broad range of tissues is to be examined histopathologically to determine the full range of responses of transgenic models (Table 111 ). Tumor genotyping, as appropriate, will be performed to better understand the genetics of the tumor response. Studies are currently underway in approximately 45 participating laboratoriks. It is anticipated that most assays will be completed by mid 1999. Issues under discussion include the identification of the most important end points for evaluation (i.e., tumor multiplicity, tumor histology, number of positive animals, etc.), the criteria for data evaluation, the potential need for specific histologic diagnostic criteria for certain tumor end points, the matter of guidance for potential tumor genotyping, and the appropriate statistical techniques.
The results of the collaborative research program will be presented during a workshop in late 1999. The workshop will provide a forum for discussion by the broader scientific community of the evolving state of the science regarding the development and application of new test methodologies for the assessment of the carcinogenic potential of chemicals. Following the workshop, the data will be published as a compendium, including appropriate analyses and comparisons, discussion of the issues raised by the data, and recommendations for future application of the assays relative to risk assessment.
